biorestorative.com (BRTX) - חוב לטווח קצר להון

The linear price action on the chart for BioRestorative Therapies (BRTX) is recorded at 0.01. The business relies on the development of cellular products to treat spinal pain, leveraging ThermoStem patent protection and stringent regulatory requirements to stifle competition. Active R&D development is focused on preparing data for BRTX-100, aligning with management's strategy to capture the untapped segment of degenerative pathology therapies.

To assess the fundamental stability of BioRestorative Therapies (BRTX), it is critical for investors to determine the share of short-term liabilities within the equity structure to measure insolvency risk over the immediate horizon. Analyzing the ratio of short-term accounts payable to equity helps determine how effectively the company finances costly cell therapy developments as it strives for market dominance in the absence of direct competitors.